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abstract
Women with cervical cancer, especially those with advanced disease, appear to experience suffering that is
more prevalent, complex, and severe than that caused by other cancers and serious illnesses, and approxi-
mately 85% live in low- andmiddle-income countries where palliative care is rarely accessible. To respond to the
highly prevalent and extreme suffering in this vulnerable population, we convened a group of experienced
experts in all aspects of care for women with cervical cancer, and from countries of all income levels, to create an
essential package of palliative care for cervical cancer (EPPCCC). The EPPCCC consists of a set of interventions,
medicines, simple equipment, social supports, and human resources, and is designed to be safe and effective
for preventing and relieving all types of suffering associated with cervical cancer. It includes only inexpensive and
readily available medicines and equipment, and its use requires only basic training. Thus, the EPPCCC can and
should be made accessible everywhere, including for the rural poor. We provide guidance for integrating the
EPPCCC into gynecologic and oncologic care at all levels of health care systems, and into primary care, in
countries of all income levels.
JCO Global Oncol 7:873-885. © 2021 by American Society of Clinical Oncology
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INTRODUCTION
Cervical cancer, a preventable disease, is the fourth
most common cancer in women globally and dis-
proportionately afflicts the poor. The International
Agency for Research on Cancer estimates that, in
2018, 570,000 women were diagnosed with cervical
cancer and 311,000 women died of it. More than
85% of cases occurred in low- or middle-income
countries (LMICs) or among socieconomically dis-
advantaged communities in high-income countries,
and it was the most common cause of cancer-related
death in sub-Saharan Africa.1 We described the
geographic distribution of cervical cancer and of
cervical cancer mortality in more detail elsewhere.2
The WHO Global Strategy to Accelerate the Elimi-
nation of Cervical Cancer as a Public Health Prob-
lem, adopted by the 73rd World Health Assembly in
August 2020, outlines a comprehensive roadmap
toward elimination within the current century that
entails achievement of the 90-70-90 targets asso-
ciated with three main pillars of the strategy: (1)
primary prevention through human papillomavirus
vaccination, (2) timely screening (by age 35 years
and again by age 45 years), and (3) treatment of
precancerous lesions and management of invasive
cervical cancer, including palliative care.3
Elsewhere, we also reported our finding that women
who died of cervical cancer in 2017 (decedents), and
women who had cervical cancer in 2017 but did not
die that year (nondecedents), experienced suffering
that was more prevalent, complex, and severe than
that caused by other malignancies and serious
illnesses.2 According to our estimates, decedents had
a high prevalence of moderate or severe pain (84%),
vaginal discharge (66%), vaginal bleeding (61%), or
loss of faith (31%). Among both decedents and
nondecedents, we estimated a high prevalence of
clinically significant anxiety (63% and 50%, respec-
tively), depressed mood (52% and 38%, respectively),
and sexual dysfunction (87% and 83%, respectively).
Moderate or severe financial distress was found to be
prevalent among decedents, nondecedents, and
family caregivers (84%, 74%, and 66%, respectively).
More than 40% of decedents and nondecedents were
abandoned by their intimate partners. In comparison,
the Lancet Commission on Palliative Care and Pain
Relief reported a lower average prevalence among
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many symptoms including moderate or severe pain (80%
and 20%, respectively), bleeding (10% and 2%, respec-
tively), anxiety (38% and 25%, respectively), and de-
pressed mood (47% and 18%, respectively).4 The Lancet
Commission did not estimate the prevalence of social or
spiritual suffering or types of suffering especially prevalent
among women with cervical cancer. We also found that
most patients with cervical cancer experienced multiple
types of moderate or severe physical, psychological, social,
and spiritual suffering. In total, 258,649 decedents and
2,558,857 nondecedents needed palliative care in 2017,
approximately 85% of whom were in LMICs where palliative
care is rarely accessible.4–7 These data indicate that pal-
liative care is indispensable for optimum care of women
with cervical cancer and their family caregivers. The data
also provide an evidence base for design of an essential
package of palliative care for this population that can be
provided even in the poorest settings.
We convened a group of experienced experts in all aspects
of care for women with cervical cancer, and from countries
of all income levels, to create an essential package of
palliative care for cervical cancer (EPPCCC) based on our
research on palliative care needs of women with cervical
cancer.8 We proceeded by adapting the essential package
of palliative care developed by the Lancet Commission on
Palliative Care and Pain Relief4,9 and the WHO essential
package of palliative care for primary health care10 to meet
the specific needs of women with cervical cancer. The
medicines in the EPPCCC were selected based on the 2019
WHOModel List of Essential Medicines for palliative care for
adults and children11,12 and on the following criteria:
• Necessary to prevent or relieve the specific symptoms or
types of suffering most common among women with
cervical cancer;
• Safe prescription or administration requires a level of
professional competency achievable by doctors, clinical
officers, assistant doctors, or nurses with basic training in
palliative care;
• Offer the best balance in their class of accessibility on the
world market, clinical effectiveness, safety, ease of use,
and minimal cost.
What Is Palliative Care for Women With Cervical Cancer?
The WHO has defined palliative care as care that improves
the quality of life of patients and their families facing the
problems associated with life-threatening illness, through
the prevention and relief of suffering by means of early
identification and impeccable assessment and treatment of
pain and other problems, physical, psychosocial, and
spiritual.13 In our view, the essence of palliative care is
prevention and relief of suffering, and the problems as-
sociated with life-threatening illness also may occur with
non–life-threatening conditions. For example, women with
early-stage, curable cervical cancer may suffer from
abandonment, depression, or treatment-related acute pain,
and long-term cervical cancer survivors may suffer from
chronic pain. The specific types and severity of suffering
vary by illness, geopolitical situation, socioeconomic con-
ditions, and culture.14
Palliative care is a people-centered accompanying of pa-
tients and their families throughout the illness course, not
only at the end of life. It should be integrated with and
complement cervical cancer prevention, early diagnosis,
treatment, and survivorship care, and it should be provided
in all health care settings including hospitals, long-term
care facilities, community health centers (CHCs), and in
patients’ homes.14–16 Doctors, nurses, psychologists, social
workers, and community health workers (CHWs) who
provide care for patients with cervical cancer should have at
least basic training in palliative care that enables them to
respond effectively to the specific types of suffering in their
setting.9,17 Complex or refractory suffering can be relieved
CONTEXT
Key Objective
Based on our previous study of the major types, prevalence, severity, and duration of suffering associated with cervical cancer
and thus of the need for palliative care, we created an essential package of palliative care for cervical cancer (EPPCCC).
Knowledge Generated
The EPPCCC consists of a set of interventions, medicines, simple equipment, and social supports that can be applied by any
clinicians with basic palliative care training. It is designed to be safe, effective for preventing and relieving all types of
suffering of inpatients and outpatients with cervical cancer, useful at all levels of health care systems, and affordable even in
the poorest settings.
Relevance
By assuring accessibility of the EPPCCC for all patients with cervical cancer at all levels of health care systems, governments
can improve patient outcomes, provide financial risk protection for patients and families, and reduce costs to the health
care system.
Krakauer et al
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most effectively by specialists in palliative care or other
disciplines.
Why Must Palliative Care Be Integrated Into Care and
Treatment for Women With Cervical Cancer?
Medical and moral imperatives. The human right to the
highest attainable standard of health entails a human right
to pain relief and palliative care for anyone with serious
illness-related suffering.18–20 The human right of palliative
care is especially compelling for women with cervical
cancer because their suffering often is more frequent,
severe, complex, or refractory than that of people with other
serious illnesses. This is true not only because of the
physical symptoms of cervical cancer, adverse effects of
treatment, and multisystem involvement of advanced dis-
ease, but also because cervical cancer disproportionately
affects the poor who often lack access to prevention, early
diagnosis, and treatment, who already have late-stage
disease at diagnosis in nearly 80% of cases, who often
lack financial resources to access treatment when it is
available, and who are at risk for stigmatization in some
places.
Human rights necessarily correspond to responsibilities of
governments to respect these rights. In 2014, the World
Health Assembly resolved that palliative care is an ethical
responsibility of health systems. 15 It is a responsibility in
part because it is feasible anywhere. Most suffering be-
cause of serious illnesses, including cervical cancer, can be
relieved with inexpensive, safe, and effective medicines,
equipment, therapies, and social supports provided by
clinicians with basic palliative care training, including those
working at community level where most patients are and
wish to remain.9
Financial benefits for patients, their families, and health care
systems. Well-planned integration of basic palliative care
into public health care systems can improve their perfor-
mance and promote universal health coverage (UHC) while
also reducing costs.4 Data from high-income countries and
upper-middle–income countries show that, when palliative
care is integrated into health care systems and includes
home care, it can reduce length of stay in hospitals and
reduce unnecessary hospital admissions for symptom relief
by enabling many patients to remain comfortable at home
or in the community.9 Hence, palliative care can reduce
hospital overcrowding and costs for overburdened health
systems and provide financial risk protection for patients
and their families.4,21–31 Within hospitals, the presence of a
palliative care inpatient unit or consultation service also can
improve patients’ quality of life and reduce costs, not only
by reducing length of stay but also by reducing use of
expensive life-sustaining treatments and cancer chemo-
therapy near the end of life likely to be more harmful than
beneficial.32–35 Although data on cost effectiveness of
palliative care in low- and lower-middle–income countries is
scant, it appears that the start-up costs necessary to
integrate a basic package of palliative care services into
health care systems—investment in policy development,
essential medicine procurement, training, and increased
staffing—may yield even better returns over time by re-
ducing costs for health care systems, reducing dysfunc-
tional overuse of hospitals and nonbeneficial interventions,
improving patients’ quality of life without shortening it,
protecting patient’s families from impoverishment, and
improving satisfaction of family caregivers.4,26,36–38
UHC, as defined by WHO, requires that all individuals and
communities receive the full spectrum of essential, quality
health services they need, from health promotion to pre-
vention, treatment, rehabilitation, and palliative care,
without suffering financial hardship.39 Because palliative
care is an essential part of UHC, UHC is achievable only if
palliative care is fully integrated into health care systems so
as to be universally accessible. In low-income settings
where palliative care is not widely accessible, when further
treatment of serious illnesses is no longer available, af-
fordable, or desired, patients often are sent home with no
further health care coverage. In these situations in par-
ticular, UHC is achievable only through implementation of
community- and home-based palliative care.10,40,41
Thus, it is not only medically and morally imperative, but
also financially advantageous, that at least a basic package
of cost-effective palliative care be integrated with treatment
of cervical cancer and universally accessible to women with
cervical cancer at all levels of health care
systems.9,10,15,42,43
ESSENTIAL PACKAGE OF PALLIATIVE CARE FOR
CERVICAL CANCER
The EPPCCC—for all women with cervical cancer and their
family caregivers—is intended to provide health care pol-
icymakers, planners, implementers, and managers from
countries of all income groups, as well as clinicians and
advocates for palliative care and cervical cancer care, with
the information necessary to integrate appropriate palliative
care into all levels of care for women with cervical cancer
and their family caregivers.8 Specifically, the EPPCCC is
designed:
• To improve patient outcomes by preventing and relieving
the most common and severe types of physical, psy-
chological, social, and spiritual suffering associated with
cervical cancer;
• To be theminimum package that should be accessible in
hospitals of all levels and at CHCs;
• To be made universally accessible free of charge by
public health care systems in LMICs yet also to reduce
costs for health care systems by reducing hospital ad-
missions and length of stay;
• To provide financial risk protection for patients and their
families; and
• To promote UHC.
The EPPCCC consists of (Table 1):
Essential Package of Palliative Care for Cervical Cancer
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TABLE 1. Essential Package of Palliative Care for People Affected by Cervical Cancer
Intervention
Inputs
Medicinesa Equipment Social Supportsb Human Resourcesc
Prevention and relief of





Dexamethasone, oral and injectable
Diazepam, oral and injectable
Diphenhydramine (chlorpheniramine,
cyclizine, or dimenhydrinate), oral and
injectable
Fluconazole, oral
Fluoxetine (sertraline or citalopram), oral
Furosemide, oral and injectable
Haloperidol, oral and injectable
Hyoscine butylbromide, oral and
injectable
Ibuprofen (naproxen, diclofenac or
meloxicam), oral
Lactulose (sorbitol or polyethylene
glycol), oral
Loperamide, oral
Metaclopramide, oral and injectable
Metronidazole, oral (for both oral use and
vaginal insertion)




Ondansetron, oral and injectablee
Oxygen
Paracetamol, oral















(if no access to
electricity)
Adult diapers or cotton
and plastic




(with basic palliative care
training)
Nurses (with basic palliative
care training)
CHWs (if available)





Dexamethasone, oral and injectable
Diazepam, oral and injectable
Diphenhydramine (chlorpheniramine,
cyclizine, or dimenhydrinate), oral and
injectable
Fluoxetine (sertraline or citalopram), oral
Haloperidol, oral and injectable
Lactulose (sorbitol or polyethylene
glycol), oral
Adult diapers or cotton
and plastic




(with basic palliative care
training)




counselors, or trained and
supervised lay counselors
CHWs (if available)
Prevention and relief of
social suffering, acute
or chronic
Cash transfers or resource allocation
for housing, children’s school
tuition, transportation to health
care facilities, or funeral costs
Other resource allocation (in-kind
support): food packages,





Prevention and relief of
spiritual suffering
Local spiritual counselors
NOTE. Adapted from Knaul et al,4 Krakauer et al,9 and World Health Organization.10
Abbreviation: CHW, community health worker.
aBased on the WHO Model List of Essential Medicines 2019.11 Acceptable alternative medicines are in parentheses.
bAt least for patients living in extreme poverty and for one caregiver per patient.
cDoctors may be oncologists, gynecologists, surgeons, general practitioners, family doctors, clinical officers or assistant doctors, or others.
dOther physical suffering includes breathlessness, weakness, nausea, vomiting, diarrhea, constipation, incontinence, malodorous vaginal discharge, and
bleeding.
eOnly in hospitals that provide cancer chemotherapy or radiotherapy.
fPsychological suffering includes anxiety, depressed mood, PTSD, confusion or delirium, sexual dysfunction, and complicated grief.
Krakauer et al
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• A set of four interventions;
• A set of safe, effective, inexpensive, off-patent, and
widely available medicines;
• Simple and inexpensive equipment;
• Basic social supports; and
• The human resources needed to provide the medicines,
equipment, and social supports effectively and safely.
Interventions
Prevention and relief of pain and other physical symptoms.
In most cases, pain and other physical suffering can be
adequately relieved with a set of safe, effective, and in-
expensive medicines that can be prescribed responsibly by
doctors, clinical officers, or assistant doctors with basic
training in palliative care or by palliative care nurse
specialists.
Morphine, in oral fast-acting and injectable preparations, is
the most clinically important of the essential palliative care
medicines and should be accessible by prescription for
inpatients and outpatients with appropriate need at any
hospital.44 In general, at least oral fast-acting morphine
should be accessible by prescription at CHCs. All doctors
who provide care for patients with cervical cancer, in-
cluding primary care doctors, should complete at least
basic palliative care training and, on that basis, receive legal
authorization to prescribe oral and injectable morphine for
inpatients and outpatients in any dose necessary to provide
adequate relief as determined by the patients.10,15
Although ensuring access to morphine for anyone in need
is imperative, it also is necessary to take reasonable pre-
cautions to prevent diversion and nonmedical use. Model
guidelines for this purpose are available.45
Neuropathic pain is common in advanced cervical cancer
and often cannot be adequately controlled with an opioid.
In this situation, oral amitriptyline and oral or injectable
dexamethasone can be used as adjuvants to improve
analgesia if there are no absolute contraindications to their
use. To reduce or eliminate malodorous vaginal discharge,
the patient can be instructed to place a metronidazole
tablet 250 mg intravaginally twice per day and advance it
gently to minimize risk of bleeding. In addition, two met-
ronidazole 250 mg tablets can be crushed to a fine powder
and sprinkled onto the pads used to absorb vaginal dis-
charge each time the pad is changed. Among the other
essential palliative medicines are oral and injectable hal-
operidol and oral fluoxetine or another selective serotonin
reuptake inhibitor (SSRI) (see section below on prevention
and relief of psychological suffering).
Essential equipment includes locked safe-boxes for opioids
that should be secured to a wall or immovable object,
elastic compression bandages for leg edema, and urinary
bladder catheter kits to manage bladder dysfunction or
outlet obstruction. Eco-friendly adult diapers, or cotton and
large plastic bags to make adult diapers, also are essential
to manage urinary or fecal incontinence because of ves-
icovaginal or rectovaginal fistulas. In countries where
plastic bags are prohibited as part of laudable environ-
mental protection initiatives, specialized medical use
should be permitted.
The necessary human resources depend primarily on the
level and type of the health care delivery site and on the
competency in palliative care of staff members rather than
their professional designations. Any medical doctor, clinical
officer, or assistant doctor with basic palliative care training
should be able to prevent or relieve most pain and other
physical suffering and to diagnose and treat uncomplicated
anxiety disorders, depression, or delirium. In some places,
nurse practitioners, midwives, or feldshers with basic
palliative care training also can assume these tasks. CHWs
can have a crucial role in palliative care by visiting patients
and family caregivers frequently at home and reporting any
problems (see section below on integration of palliative care
for women with cervical cancer into primary care).
Prevention and relief of psychological suffering. Among
women with cervical cancer, the high prevalence of anxiety,
depressed mood, sexual dysfunction, and other psycho-
logical disorders, the suffering they cause, and the asso-
ciation of untreated psychological disorders with decreased
treatment adherence necessitate assiduous efforts to
prevent, promptly diagnose, and treat them.2,46–50 Family
members of patients with cancer also may experience
psychological distress because of fear of losing a loved one,
caregiving burden, poverty because of loss of income and
medical expenses, or prolonged grief disorder after the
patient’s death.51,52
A small set of screening tools, counseling techniques, and
medicines should be used not only by palliative care
specialists but also by oncologists, gynecologists, and
primary care doctors. Two practical screening tools for
psychological and other types of distress are the Integrated
Palliative Care Outcome Scale and the distress thermom-
eter of the US National Comprehensive Cancer
Network.53–55 Among the medicines in the EPPCCC are oral
and injectable haloperidol and oral fluoxetine or another
SSRI. Both have multiple essential uses in palliative care
and are safe and easy to prescribe. For example, halo-
peridol is the first-line medicine in many cases for relief of
nausea, vomiting, agitation, delirium, and anxiety. An SSRI,
such as fluoxetine, is the first-line pharmacotherapy for
depressed mood or persistent anxiety, both of which are
common among women with cervical cancer and their
family caregivers. Any doctor who provides primary care
should be prepared and permitted to prescribe these
medicines. Patients with severe or refractory psychiatric
illnesses should be referred for specialist psychiatric care
whenever possible.
Nonpharmacologic interventions for psychological distress
include psychotherapy; supportive counseling;
Essential Package of Palliative Care for Cervical Cancer
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psychoeducation; relaxation, art, music, and movement
therapies; and guided imagery techniques.56 The goals of
these interventions are:
• to improve coping skills and resilience,
• to reduce emotional distress,
• to reduce feelings of depression and anxiety,
• to improve body image and to help the patient to regain
self esteem,
• to enhance personal growth,
• to strengthen the personal and social resources of the
patient and her caregivers, and
• to improve quality of life
Not only doctors, nurses, psychologists, and social workers,
but also CHWs can be trained to provide simple, culturally
appropriate supportive counseling and even psychotherapy
for depression.57–59
Treatment of psychological suffering may have the added
benefit of improving control of the patient’s pain, fatigue,
nausea, or other physical symptoms. It also can facilitate
advance care planning, discussion of goals of care and
treatment options, and bereavement.56,60
Prevention and relief of social suffering. Social supports are
especially important for women with cervical cancer in light
of the finding of a high prevalence of financial difficulties,
discrimination, stigmatization, social isolation, and aban-
donment in this population.2 Social support for patients and
family caregivers living in poverty is needed to ensure that
their most basic needs are met such as food, housing, and
transport to health care facilities, and to promote dignity.9,10
These supports should include, as appropriate, basic food
packages, housing or cash payments for housing, trans-
portation vouchers for visits to clinics or hospitals for the
patient and a caregiver, and in-kind support, such as
blankets, sleeping mats, shoes, soap, toothbrushes, and
toothpaste.61,62 This type of social support helps to ensure
that patients can access and benefit frommedical care and
should be accessible by any patient, and not only those in
need of palliative care or symptom control. Patients should
be asked about perceived discrimination or stigmatization,
and counseling should be made accessible by social
workers with academic training or experience in addressing
these problems. Provision also should be made for women
facing discrimination in housing, employment, or educa-
tion, and for those abandoned by their intimate partners or
families, to access free or affordable legal services. Psy-
chological and social supports should be closely coordi-
nated. In addition, because culturally appropriate burial
can be a major financial burden for families and inability to
provide a funeral can become a chronic emotional burden,
locally adequate funds for a simple funeral should be made
accessible for families living in extreme poverty.
Prevention and relief of spiritual suffering. Spiritual distress
is prevalent in advanced cancer,63 yet available evidence
suggests that this distress typically is not adequately
addressed.64–66 Serious illness and related suffering may
catalyze meaning-making but also a questioning of reli-
gious belief and of the meaning of life.67,68 Illness and
suffering may be interpreted as divine punishment or a
result of bad magic.69,70 Stigma associated with disease of
the genitals, malodorous vaginal discharge, or concurrent
HIV infection may evoke feelings of humiliation, guilt, or
shame.71,72 This suffering or shame may lead to moral
despair, anger with a higher power, loss of faith, or loss of
the ability to findmeaning in life. Family caregivers also may
experience spiritual despair.73,74
Hospitals of all levels, CHCs, and palliative care or hospice
teams should establish and maintain collaborative rela-
tionships with local spiritual counselors representing the
main religious or spiritual communities in the catchment
area who can be called upon to provide spiritual support
when requested by a patient or family. Any doctor, nurse,
psychologist, or social worker, regardless of spiritual ori-
entation, can screen for spiritual distress by asking patients
with serious illnesses about sources of meaning and hope
and connectedness with others.75 If there is concern about
spiritual distress based on the screening, or if the patient
requests spiritual counseling, a local spiritual care provider
can be consulted. A doctor, nurse, psychologist, or social
worker should speak with the potential spiritual provider in
advance to explain the emotional delicacy of such situa-
tions and to minimize the risk of inadvertent exacerbation of
a patient’s feelings of guilt or shame from spiritual coun-
seling. Ideally, the spiritual provider first should conduct a
more thorough spiritual assessment using an existing as-
sessment model adapted to local culture.76–79 Based on the
assessment, an appropriate plan of spiritual care can be
developed. Sometimes, this may entail involvement of
traditional healers. Spiritual support may help some pa-
tients or their family caregivers to make meaning of the
illness, to cope better, to feel less afraid or ashamed, or to
feel more at peace.70,80–82
Integrating Palliative Care Into Standard Practice of
Gynecologic Oncology
Locations of care. The EPPCCC should be accessible
wherever women with cervical cancer seek or receive care
as shown in Table 2.15,83 In LMICs, where cervical cancer
typically is diagnosed at an advanced stage at a provincial
or regional general hospital or cancer center (second- or
third-level hospital), all such hospitals should have a pal-
liative care department or team with capacity to assess all
newly diagnosed inpatients and outpatients for physical,
psychological, social, or spiritual suffering. These teams
also should be able to initiate palliative care, to integrate it
with disease-modifying treatments early as part of the
overall treatment plan, to create a plan for continued
palliative care at lower levels or at home for outpatients
and for inpatients before discharge, and to control re-
fractory symptoms that cannot be controlled at lower
levels.84,85 When difficult decisions about goals of care
Krakauer et al
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must be made, palliative care team members should be
prepared to assist.
All district (first-level) hospitals should have at least one or
two doctors and nurses with at least basic palliative care
training who are assigned to provide basic palliative care
with the EPPCCC as one of their responsibilities. WHO has
published a model training curriculum in basic palliative
care for doctors, clinical officers, or assistant doctors lasting
30-40 hours.10,86 With this training, they will be capable of
addressing the needs of inpatients and outpatients with
uncomplicated palliative care needs. These needs include
adjustment in doses of opioid analgesics or other medicines
to control symptoms that are uncomplicated but changing
because of disease progression or treatment side effects.
For dying patients whose symptoms are adequately con-
trolled but whose families are unable to care for them at
home, these teams also can provide inpatient end-of-life
(hospice) care if the CHCs nearest the patient’s home are
unable to do so. Palliative care teams at district level also
have a crucial role in supervising and providing backup for
palliative care providers at community level.
At least two clinicians at every CHC—ideally at least one
doctor and one other clinician—also should have at least
basic palliative care training, and as soon as possible, all
primary care clinicians should have this training. Per WHO,
basic palliative care training lasting at least 30 hours should
enable trainees to provide basic outpatient symptom
control and supervise CHWs who visit patients at home.10
Standard operating procedures should be in place to as-
sure easy communication and smooth transfer of patients
between levels of the health care system.10
Basic and more advanced courses in palliative care are
offered in some LMICs in all regions by hospitals, univer-
sities, or nongovernmental organizations. A directory of
palliative care training programs is maintained by the In-
ternational Association for Hospice and Palliative care.87
However, the need for all levels of palliative care training in
LMICs remains high, and specialist training program are
available only in a few countries. Likewise, even basic
palliative care services and many essential palliative
medicines, includingmorphine, remain unavailable to most
inpatients and outpatients in LMICs.6
Assessment for physical, psychological, social, or spiritual
suffering is indicated at the time of diagnosis of cervical
cancer of any stage, and palliative care should be initiated
based on the assessment.10 In LMICs, pain, vaginal dis-
charge, vaginal bleeding, anxiety, depression, sexual
dysfunction, or social distress often are present at the time
of diagnosis and require palliation, regardless of the
treatment plan and whether or not cure is possible.2 As the
treatment plan is formulated, palliative care also entails
helping patients and possibly their families, as appropriate,
to understand the illness and treatment plan, helping to
assure that the patient has the resources to adhere to the
treatment, providing emotional support, and sometimes
helping to reach an agreement between the patient, family,
and treatment team on the optimum goal(s) of care in light
of the clinical situation and the patient’s values.
During treatment with radiotherapy, chemotherapy, or
surgery, palliative care entails continued relief of any
disease-related symptoms but also prevention and relief of
any adverse effects of treatment, some of whichmay persist
for months or years after treatment is completed. It also
entails continued psychological, social, and spiritual sup-
port as needed to maximize the patient’s ability to cope with
the illness and adhere to treatment.
All gynecologists who care for patients with cervical cancer
and all oncologists should have intermediate-level palliative
care training (defined by WHO as 60-80 hours) and be
capable of integrating palliative care with disease treatment
along with nurses and psychologists or social workers.10
Provision of effective palliative care does not always require
much time from busy oncologists or gynecologists but
rather a recognition of its importance and adequate
training. Plans should be made for palliative care teams at
major cancer centers in LMICs to be led as soon as possible
by palliative care specialists skilled at relieving even
complex and refractory symptoms. Elsewhere, we describe
an augmented package of palliative care that should be
made available whenever feasible at major cancer centers
for specialists in palliative medicine and other disciplines to
treat themost severe or refractory suffering.85 Palliative care
specialists also should participate in person or virtually in
tumor board discussions. However, most palliative care can
and should be provided by other medical specialists and by
primary care clinicians.
Integration of palliative care for women with cervical cancer
into primary care. All 194 WHO member states have
agreed that palliative care is an essential function of primary
care and should be integrated with disease prevention and
treatment and rehabilitative services.10,15,88,89 Thus, all
primary care doctors and other primary care clinicians,
including family medicine specialists, should be required to
undergo at least basic palliative care training (30-40 hours).
With this training, and with the EPPCCC, primary care
clinicians at district (first-level) hospitals and CHCs will be
able to provide integrated, people-centered health services
for women suffering from or at risk for cervical cancer
including human papillomavirus vaccination, cervical
cancer screening, relief of uncomplicated disease-related
symptoms and adverse effects of treatment, psychosocial
and adherence support, and basic end-of-life care.89-92
Standard operating procedures should be in place to en-
able primary care clinicians to consult colleagues at higher
levels about difficult cases and to transfer patients when
necessary.10 Doctors and other clinicians at CHCs also can
supervise CHWs or volunteers who visit patients in need of
palliative care at home.10 With as little as 3 to 6 hours of
training, CHWs or volunteers not only can provide important
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emotional support, but also recognize uncontrolled
symptoms and improper use of medicines, identify un-
fulfilled basic needs for food, shelter, or clothing, and
generally serve as the eyes and ears of their clinician-
supervisors at a CHC by alerting them via mobile phone
to such problems.9,10 Where there are no CHWs, provision
should be made for clinicians from CHCs to visit patients at
home. Health care systems also should plan to enable busy
clinicians from CHCs to make home visits when a visit may
enable a patient to remain comfortable at home rather than
go to the hospital.
End-of-life care. When any further disease-modifying treat-
ment is deemedunlikely to provide benefit in the context of the
patient’s values, or likely would be more harmful than ben-
eficial, a conversation about goals of care with the patient and/
or family is necessary. The prognostic understanding of the
patient or family should be explored gently and corrected as
needed and as culturally appropriate, and it should be
explained that care tomaximize comfort and quality of lifemay
be the best that medicine can offer under the circumstances.
Whether this situation occurs in the hospital or in the com-
munity, good end-of-life care should include
• Aggressive relief of pain and any other physical or psy-
chological symptoms;
• Anticipation of symptoms that might worsen or develop in
the future, and preparation of a plan to protect the patient
from resultant suffering;
• Decisions about location of care and under what cir-
cumstances, if any, transfer to higher or lower level
should be considered;
• Psychological, social, or spiritual support as needed.
If there is agreement on comfort as the sole goal of care for a
patient in the hospital, and if one or more symptoms are not
well controlled, the patient should remain in the hospital or
in an inpatient hospice or palliative care facility at least until
a regimen is found to maintain comfort. For patients likely to
die within a few days or on the way home, discharge should
be considered only if the patient insists after understanding





Specialty) Hospitals First-Level (District) Hospitals CHCs










about goals of care
Planning for care at
home or at lower
level
Social supports
Palliative care team consisting of
full- or part-time doctors with
at least intermediate-level
training in palliative care,
nurses, psychologist, and/or
social worker
Ideally, a palliative care specialist
physician should lead the
team at major cancer centers
and referral hospitals
Inpatient palliative care ward
Outpatient palliative care clinic
Consultation by phone for
clinicians at lower level, as
needed
Small palliative care team
consisting of one or two part-
time doctors with basic or
intermediate-level training in
palliative care, nurse(s), and
ideally also a social worker
Inpatient palliative care






Small palliative care team
consisting of one or two part-
time doctors with basic or
intermediate-level training in
palliative care, nurse(s), and
ideally also a social worker
Inpatient hospice care if the
family is unable to provide
adequate care at home and if
no inpatient care is available
at CHCs
Outpatient palliative care clinic
Supervision of palliative care at
lower level
Nurse(s) or midwives and
possibly also a doctor,
social worker, or lay
counselor with basic
training in palliative care to
provide outpatient care and
home visits as needed
Ideally also inpatient hospice
care if the family is unable
to provide adequate care at
home
CHWs provide surveillance
and emotional support as
often as daily
Visits as needed by a nurse,
doctor, social worker, or
trained lay counselor from
the CHC with basic
training in palliative care
NOTE. Adapted from Krakauer et al9 and World Health Organization.10
Abbreviations: CHC, community health center; CHW, community health worker.
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the risks or if dying at home appears to be of over-riding
importance according to the patient’s values. When dis-
charge is being considered, the home situation should be
carefully assessed to make sure that adequate palliative
care can be provided in the home and that the well-being of
family caregivers would not be jeopardized.93 An alternative
would be for terminally ill patients whose symptoms are well
controlled but whose families cannot care for them at home
to be allowed to receive end-of-life care at a CHC that is
staffed around the clock. This would enable the family to
visit without having the burden of providing 24-hour care
and would be less expensive than having the patient in a
hospital.9,10
Women with advanced cervical cancer are at risk for var-
ious sudden and/or severe symptoms including pain crisis,
bowel obstruction, and massive vaginal hemorrhage with
exsanguination. When planning the location of end-of-life
care, the risk of these or other severe complications should
be considered carefully with the patient and/or family.
Elsewhere, we describe interventions to prevent or control
massive hemorrhage as part of an augmented package of
palliative care for women with cervical cancer that should
be made available as soon as feasible in major cancer
centers.85 However, where such interventions are not
available or desired, or if the patient insists on going home
despite uncontrolled symptoms or high risk of sudden or
severe suffering, every effort still should be made to inform
and equip community-based primary care clinicians to
provide the best possible palliation. In particular, if there is a
significant risk of massive hemorrhage, community providers
and family members should be instructed to havemany dark
towels available to catch the blood and given the following
guidance on how to respond when bleeding occurs:
• A primary care provider should go to the patient’s home
and reassure the patient and family members that the
situation will be managed.
• Any CHW or volunteer who knows the family should go to
the home to offer accompaniment to the patient and
family through the event.
• The dark towels should be used to catch the blood and
replaced when soaked.
• An intravenous (IV) or subcutaneous catheter should be
placed promptly, and any pain or anxiety of the patient
should be treated aggressively with IV or subcutaneous
opioid and benzodiazepine.
• Any dyspnea or chest pain that occurs as the patient
exsanguinates should be relieved aggressively with IV
opioid.
• Vaginal packing with roller gauze may be considered but
often exacerbates discomfort.
When a decision is made that the sole goal of care will be
comfort, some women may find meaning or solace in pre-
paring a simple legacy for their children or other family
members such as a letter or memory box. Local volunteer
spiritual supporters should be sought to provide culturally
appropriate spiritual support if requested by the patient, and
bereavement support should also be made accessible.10,94
In conclusion, based on available data of palliative care
needs among women with cervical cancer, we created an
EPPCCC that consists of safe, effective, readily available,
and inexpensive medicines, simple equipment, and social
supports that can and should be administered as part of
standard gynecologic, oncologic, and primary care by
clinicians with at least basic training in palliative care. In-
tegration of the EPPCCC into care for women with cervical
cancer should be part of the overall integration of palliative
care into health care systems as urged by WHO that is
indispensable to achievement of UHC. However, women
with cervical cancer appear to bear an unusually high
burden of suffering that calls for a vigorous response from
public health officials, gynecologists, oncologists, and
primary care providers.
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